Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Needham analyst Mike Matson maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price target from $7 to $10.
Personalis (NASDAQ:PSNL) lowers FY2025 sales outlook from $70.000 million-$80.000 million to $68.000 million-$73.000 million vs...
Personalis (NASDAQ:PSNL) sees Q4 sales of $15.700 million-$20.700 million vs $21.769 million analyst estimate.
Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.28) by...
BTIG analyst Mark Massaro maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price target from $6 to $11.
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca ph...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Personalis (NASDAQ:PSNL) with a Buy and maintains $8.5 pri...
